Nuvation Bio's gross profit for the
three
months ended in Sep. 2024 was $-0.79 Mil. Nuvation Bio's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.70 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Nuvation Bio's gross profit for the
three
months ended in Sep. 2024 was $-0.79 Mil. Nuvation Bio's Revenue for the
three
months ended in Sep. 2024 was $0.73 Mil. Therefore, Nuvation Bio's Gross Margin % for the quarter that ended in Sep. 2024 was -108.39%.
Nuvation Bio had a gross margin of -108.39% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
Nuvation Bio Gross Profit Historical Data
The historical data trend for Nuvation Bio's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nuvation Bio's Gross Profit
For the Biotechnology subindustry, Nuvation Bio's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's Gross Profit distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's Gross Profit falls into.
Nuvation Bio Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Nuvation Bio's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.70 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nuvation Bio (NYSE:NUVB) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nuvation Bio had a gross margin of -108.39% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
Nuvation Bio Gross Profit Related Terms
Thank you for viewing the detailed overview of Nuvation Bio's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVB has been successfully added to your 